GeNesis - The Genetics and Neuroendocrinology of Short Stature International study

Head :
Médecin pharmacoépidémiologiste , Eli Lilly France

Last update : 07/08/2015 | Version : 3 | ID : 77

print
Print
xml
XML

Export to XML

Please choose the format :

pdf
PDF
xml
CSV (Excel)

Export to CSV

What sections do you want to export ?

Métadonnées
Identification
General Aspects
Scientific investigator(s) (Contact)
Collaborations
Funding
Governance of the database
Additional contact
Type of database
Database objective
Population type
Dates
Size of the database
Data
Procedures
Promotion
Access
Select all | Invert selection | No selection

Which version do you want to export ?

send
Send
General
Identification
Detailed name The Genetics and Neuroendocrinology of Short Stature International study
Sign or acronym GeNesis
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CNIL N° 999310
General Aspects
Medical area Endocrinology and metabolism
Health determinants Genetic
Keywords Growth retardation, auxological measurements, relative efficacy in actual life, children, treatment, tolerance
Scientific investigator(s) (Contact)
Name of the director Médecin pharmacoépidémiologiste
Email fr_mail_pharmacoepi@lilly.com
Unit Eli Lilly France
Collaborations
Funding
Funding status Private
Details Eli Lilly and Company
Governance of the database
Sponsor(s) or organisation(s) responsible Eli Lilly
Organisation status Private
Additional contact
Main features
Type of database
Type of database Study databases
Study databases (details) Cohort study
Database recruitment is carried out by an intermediary A selection of health institutions and services
Database recruitment is carried out as part of an interventional study No
Additional information regarding sample selection. For France: recruitment of patients by endocrinologists, pediatricians and pediatric endocrinologists involved in caring for children with a growth disorder and in prescribing growth hormone treatments and located all across the territory
Database objective
Main objective Evaluate the safety and effectiveness of the treatment via recombinant human growth hormone (Humatrope) using observation data.
Inclusion criteria Children having a growth disorders whether or not treated via somatropin
Population type
Age Childhood (6 to 13 years)
Population covered Sick population
Gender Male
Woman
Geography area International
Detail of the geography area about 30 countries
Data collection
Dates
Date of first collection (YYYY or MM/YYYY) 2000
Date of last collection (YYYY or MM/YYYY) 2015
Size of the database
Size of the database (number of individuals) [10 000-20 000[ individuals
Details of the number of individuals 9697 (03/10/2012)
Data
Database activity Current data collection
Type of data collected Clinical data
Biological data
Clinical data (detail) Direct physical measures
Medical registration
Biological data (detail) Fasting glucose, biochemical indicators of the secretion of GH, hormone assays, urine bone marker assays, IGF-1 and IGFBP-3 assays
Presence of a biobank Yes
Contents of biobank DNA
Details of biobank content non-systematic biobank
Health parameters studied Health event/morbidity
Procedures
Data collection method Data collection notebook
Participant monitoring Yes
Details on monitoring of participants follow-up until final size
Links to administrative sources No
Promotion and access
Promotion
Link to the document http://www.hal.inserm.fr/GENESIS
Description List of publications in HAL
Link to the document http://tinyurl.com/Pubmed-Cohorte-GENESIS
Description List of publications in Pubmed
Access
Terms of data access (charter for data provision, format of data, availability delay) Report and publication
Access to aggregated data Access on specific project only
Access to individual data Access on specific project only

Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05

View Edit Create here